Caveolin-mediated endocytosis Sample Clauses

Caveolin-mediated endocytosis. Similar to the clathrin-coated vesicles, caveolae vesicles also originate from cholesterol-enriched invaginations of the plasma membrane. They invaginated as flask-shaped vesicles within the plane of the plasma membrane, or as detached vesicles. In addition, caveolae can fuse to form grape-like structures and tubules with sizes larger than 100 nm (Xxxxx, X.X. et al., 1999, Pelkmans, X. et al., 2001). Caveolae are mainly composed of cholesterol and sphingolipids and accumulate cholesterol binding-proteins known as caveolins, on the cytosolic face of the vesicles (Xxxxx, X.X. xx al., 1999, Xxxxxxx, X. et al., 2001, Xxxxxx, X. et al., 2002). Caveolae play a role in endocytosis of certain viruses such as simian virus 40 (SV40), as well as some bacteria and bacterial toxins such as cholera toxin (Khalil, I.A. et al., 2006) and like the clathrin pathway, calveolae require GTPases activity for the pinch off of vesicles. After internalisation, caveolae-derived vesicles fuse with caveosomes (Xxxxxxx, X.X. and X. Xxxxxxxxxx-Xxxxxxxx, 2001, Pelkmans, X. et al., 2002), which are pre- existing, stable, organelles with a neutral pH and it is believed that this uptake mechanism does not lead to lysosomal degradation (Xxxxxx, X.X., 2004). Macromolecules internalized via this route are transported to the endoplasmic reticulum (ER) (Pelkmans, X. et al., 2001) or to the trans-Golgi network (TGN) (Xxxxxx, X.X. and X. Xxxxxx, 2005) and therefore avoid lysosomal degradation. Due to its non-degradative nature (Ferrari, X. et al., 2003, Xxxxxx, X. et al., 2002), caveolar endocytosis represents an attractive pathway for gene delivery, even though this process is considered slow and has a small phase volume making it unlikely to be a primary uptake route. This uptake is also energy dependent so it can be inhibited by lowering temperature or by ATP depletion. In addition, drugs that specifically bind, sequester, or deplete cholesterol such as filipin, nystatin, and methyl-β-cyclodextrin, respectively, inhibit internalization by the caveolae (Lamaze, C. and X.X. Xxxxxx, 1995, Xxxxxxxxx, X.X. xx al., 1994). The caveloae pathway is actin-dependent and therefore drugs that affect the actin cytoskeleton such as cytochalasins are used to inhibit caveloae pathway without affecting the clathrin-mediated endocytosis, although these drugs do also inhibit macropinocytosis (Xxxxxx, X.X., 2004).
AutoNDA by SimpleDocs

Related to Caveolin-mediated endocytosis

  • Vlastnictví Zdravotnické zařízení si ponechá a bude uchovávat Zdravotní záznamy. Zdravotnické zařízení a Zkoušející převedou na Zadavatele veškerá svá práva, nároky a tituly, včetně práv duševního vlastnictví k Důvěrným informacím (ve smyslu níže uvedeném) a k jakýmkoli jiným Studijním datům a údajům.

  • Radiation Therapy/Chemotherapy Services This plan covers chemotherapy and radiation services. Respiratory Therapy This plan covers respiratory therapy services. When respiratory services are provided in your home, as part of a home care program, durable medical equipment, supplies, and oxygen are covered as a durable medical equipment service.

  • VOETSTOOTS The PROPERTY is sold:

  • Speech Therapy This plan covers speech therapy services when provided by a qualified licensed provider and part of a formal treatment plan for: • loss of speech or communication function; or • impairment as a result of an acute illness or injury, or an acute exacerbation of a chronic disease. Speech therapy services must relate to: • performing basic functional communication; or • assessing or treating swallowing dysfunction. See Autism Services when speech therapy services are rendered as part of the treatment of autism spectrum disorder. The amount you pay and any benefit limit will be the same whether the services are provided for habilitative or rehabilitative purposes.

  • Manufacturing Technology Transfer With respect to each Technology Transfer Product, upon AbbVie’s written request after the Inclusion Date for the Included Target to which such Technology Transfer Product is Directed, Morphic shall effect a full transfer to AbbVie or its designee (which designee may be an Affiliate or a Third Party manufacturer) of all Morphic Know-How and Joint Know-How relating to the then-current process for the Manufacture of such Technology Transfer Product (the “Manufacturing Process”) and to implement the Manufacturing Process at facilities designated by AbbVie (such transfer and implementation, as more fully described in this Section 5.3, the “Manufacturing Technology Transfer”). To assist with the Manufacturing Technology Transfer, Morphic will make its personnel reasonably available to AbbVie during normal business hours for up to [***] FTE hours with respect to each Included Target (in each case, free of charge to AbbVie) to transfer and implement the Manufacturing Process under this Section 5.3. Thereafter, if requested by AbbVie, Morphic shall continue to perform such obligations; provided, that AbbVie will reimburse Morphic for its full-time equivalent (FTE) costs (for clarity, in excess of [***] FTE hours) and any reasonable and verifiable out-of-pocket costs incurred in providing such assistance. CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF PUBLICLY DISCLOSED.

  • Musculoskeletal Injury Prevention and Control (a) The Hospital in consultation with the Joint Health and Safety Committee (JHSC) shall develop, establish and put into effect, musculoskeletal prevention and control measures, procedures, practices and training for the health and safety of employees.

  • COVID-19 Residents acknowledge that in March 2020 the World Health Organization declared a global pandemic of the virus leading to COVID-19. The Governments of Canada, the Province of Ontario, and local Governments responded to the pandemic with legislative amendments, controls, orders, by-laws, requests of the public, and requests and requirements to Humber (collectively, the “Directives”). It is uncertain how long the pandemic, and the related Directives, will continue, and it is unknown whether there may be a resurgence of the virus leading to COVID-19 or any mutation thereof (collectively, “COVID- 19”). Without limiting the generality of the foregoing paragraph, Humber shall not be held legally responsible or be deemed to be in breach of this Agreement for any damages or loss arising out of or caused by:

  • WSIB & LTD An Employee who is receiving benefits under the Workplace Safety and Insurance Act, or under a LTD plan, is not entitled to benefits under a school board’s sick leave and short term disability plan for the same condition unless the employee is on a graduated return to work program then WSIB/LTD remains the first payor. For clarity, where an employee is receiving partial benefits under WSIB/LTD, they may be entitled to receive benefits under the sick leave plan, subject to the circumstances of the specific situation. During the interim period from the date of the injury/incident or illness to the date of the approval by the WSIB/LTD of the claim, the employee may access sick leave and short term leave and disability coverage. A reconciliation of sick leave deductions made and payments provided, will be undertaken by the school board once the WSIB/LTD has adjudicated and approved the claim. In the event that the WSIB/LTD does not approve the claim, the school board shall deal with the absence consistent with the terms of the sick leave and short term leave and disability plans.

  • Safety Boots Each employee, after 3 months’ continuous service, will be reimbursed (on production of a receipt), the cost of one pair of safety boots (approved by the employer), in each year, to a maximum of $110.00. Wet Weather All protective clothing such as wet weather jackets, safety helmets, welding jackets, welding xxxxxxx, welding gauntlets, rubber boots, etc, (which remain the property of the Company), will be supplied on all occasions deemed necessary.

  • Technology Research Analyst Job# 1810 General Characteristics Maintains a strong understanding of the enterprise’s IT systems and architectures. Assists in the analysis of the requirements for the enterprise and applying emerging technologies to support long-term business objectives. Responsible for researching, collecting, and disseminating information on emerging technologies and key learnings throughout the enterprise. Researches and recommends changes to foundation architecture. Supports research projects to identify and evaluate emerging technologies. Interfaces with users and staff to evaluate possible implementation of the new technology in the enterprise, consistent with the goal of improving existing systems and technologies and in meeting the needs of the business. Analyzes and researches process of deployment and assists in this process.

Time is Money Join Law Insider Premium to draft better contracts faster.